Loading...

BeiGene, Ltd.

BGNE•NASDAQ
Healthcare
Biotechnology
$184.71
$0.90(0.49%)

BeiGene, Ltd. (BGNE) Stock Overview

Explore BeiGene, Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 74.4/100

Key Financials

Market Cap20.2B
P/E Ratio-112.63
EPS (TTM)$-8.19
ROE-0.05%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$140.76

BGNE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BeiGene, Ltd. (BGNE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $140.76.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -112.63 and a market capitalization of 20.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-18.53%
5-Day Change
-15.11%
1-Month Change
0.49%
3-Month Change
-10.33%
6-Month Change
17.66%
Year-to-Date (YTD) Change
0.39%
1-Year Change
19.14%
3-Year Change
-23.86%
5-Year Change
20.34%
All-Time (Max) Change
552.22%

Contact Information

https://www.beigene.com
781-801-1800
55 Cambridge Parkway, Cambridge, MA, 02142

Company Facts

10,600 Employees
IPO DateFeb 3, 2016
CountryUS

Frequently Asked Questions

;